Pharmaceutical Development and Technology最新文献

筛选
英文 中文
pH/GSH-responsive dual chitosan/PLA-coated cobalt ferrite nanoparticles for targeted and selective quinidine delivery in hepatocellular carcinoma. pH/ gsh响应的双壳聚糖/ pla包覆钴铁氧体纳米颗粒用于靶向和选择性给药奎尼丁肝细胞癌。
IF 2.9 4区 医学
Pharmaceutical Development and Technology Pub Date : 2026-10-31 DOI: 10.1080/10837450.2026.2755032
Esraa Anter, Fawzya I Elshami, Hadeer A Shereef, Safaa N Abdou, Rudi van Eldik, Shaban Y Shaban
{"title":"pH/GSH-responsive dual chitosan/PLA-coated cobalt ferrite nanoparticles for targeted and selective quinidine delivery in hepatocellular carcinoma.","authors":"Esraa Anter, Fawzya I Elshami, Hadeer A Shereef, Safaa N Abdou, Rudi van Eldik, Shaban Y Shaban","doi":"10.1080/10837450.2026.2755032","DOIUrl":"https://doi.org/10.1080/10837450.2026.2755032","url":null,"abstract":"<p><p>Drug repurposing using smart nanocarriers may help overcome chemoresistance and poor tumor selectivity in hepatocellular carcinoma (HCC). Here, a pH/GSH-responsive dual chitosan/polylactic acid coated cobalt ferrite nanoparticle system (QL-CS/PLA-CFO NPs) has been explored to deliver QL for treating HCC. QL-CS/PLA-CFO NPs were prepared via ionotropic gelation and w/o/w emulsion with high loading (64.8%) and excellent stability (+28.0 mV). Comparative formulations, chitosan-only QL-CS-CFO (50.9%, -10.5 mV) and nonmagnetic QL-CS/PLA (60.7%, -21.0 mV), elucidated the roles of coating architecture and magnetic core. QL-CS/PLA-CFO NPs released 10.8% at pH 7.4 versus ∼95% at pH 4.5 with 10 mM GSH over 180 h, following quasi-Fickian diffusion kinetics. Encapsulation increased the WI38/HepG2 IC₅₀ ratio from 1.12 to 1.93 through controlled endosomal release and protecting normal cells, with ∼1.2% hemolysis and enhanced DPPH antioxidants IC₅₀ (47.9 vs. 71.9 μg/mL for free QL). DNA-binding studies revealed PLA-CFO synergy, yielding 38-fold enhanced affinity versus free QL through a minor-groove binding mode. Molecular docking suggested a potential interaction between quinidine and the HCC-associated biomarker glypican-3 (PDB 3GJB), supporting future investigation of its biological relevance. QL-CS/PLA-CFO NPs represent a promising platform for selective QL delivery in HCC, warranting further in vivo evaluation.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1-23"},"PeriodicalIF":2.9,"publicationDate":"2026-10-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149323939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Pirfenidone-loaded hyaluosomes as a nanocarrier for the treatment of scleroderma. 负载吡非尼酮的透明质体作为纳米载体治疗硬皮病。
IF 2.9 4区 医学
Pharmaceutical Development and Technology Pub Date : 2026-10-30 DOI: 10.1080/10837450.2026.2755030
Mona Mahmoud AbouSamra, Alaa Hamed Salama, Rania Elgohary, Zeinab A Elshahid, Rana R Makar
{"title":"Pirfenidone-loaded hyaluosomes as a nanocarrier for the treatment of scleroderma.","authors":"Mona Mahmoud AbouSamra, Alaa Hamed Salama, Rania Elgohary, Zeinab A Elshahid, Rana R Makar","doi":"10.1080/10837450.2026.2755030","DOIUrl":"https://doi.org/10.1080/10837450.2026.2755030","url":null,"abstract":"<p><p>Scleroderma is a chronic autoimmune disorder marked by excessive fibrosis and skin thickening. To improve treatment efficacy, this study developed and evaluated pirfenidone-loaded hyaluosomes (PFD-HSs) as an advanced nanocarrier system for the topical delivery of the antifibrotic agent pirfenidone. The optimized formulation; PFD-HS1 composed of lipoid S100, sodium cholate, and 0.5% hyaluronic acid achieved high entrapment efficiency 90.44%, a vesicle size of 125 nm, a PDI of 0.12, and a ZP of -26 with uniform spherical morphology and sustained <i>in vitro</i> drug release over 6 h. FTIR testing confirmed changes in the drug's physical state following formulation that suggest possible intermolecular interactions, potentially including hydrogen bonding. When incorporated into a topical gel, the formulation demonstrated approximately 2.7-fold higher <i>ex vivo</i> skin permeation compared to a free pirfenidone gel after 5 h. In lipopolysaccharide-stimulated RAW 264.7 macrophages, PFD-HSs exhibited high anti-inflammatory activity compared to free drug. Furthermore, in a bleomycin-induced scleroderma rat model, the formulation significantly reduces fibrotic and inflammatory markers (TNF-α, TGF-β, Col-1, α-SMA, and TIMP1), while significantly increases MMP2 expression. These biochemical improvements were further validated by histopathological findings. Pirfenidone-loaded hyaluosomes serve as a highly promising topical nanocarrier system, offering enhanced skin delivery and superior therapeutic outcomes for scleroderma management.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1-23"},"PeriodicalIF":2.9,"publicationDate":"2026-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149299707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Natural biodegradable polymer-based microneedles for controlled drug delivery: a rational design framework and translational perspectives. 天然可生物降解聚合物微针控制药物输送:一个合理的设计框架和翻译的观点。
IF 2.9 4区 医学
Pharmaceutical Development and Technology Pub Date : 2026-10-01 Epub Date: 2026-09-24 DOI: 10.1080/10837450.2026.2737199
Khaled E Abuelella, Nermin M Sheta
{"title":"Natural biodegradable polymer-based microneedles for controlled drug delivery: a rational design framework and translational perspectives.","authors":"Khaled E Abuelella, Nermin M Sheta","doi":"10.1080/10837450.2026.2737199","DOIUrl":"10.1080/10837450.2026.2737199","url":null,"abstract":"<p><p>Microneedle (MN) technology has emerged as a promising minimally invasive platform for transdermal drug delivery, enabling efficient transport of therapeutic agents across the stratum corneum while improving patient compliance. In recent years, natural biodegradable polymers have gained increasing attention in microneedle fabrication due to their biocompatibility, biodegradability, and functional versatility. This review provides a comprehensive overview of recent advances in natural polymer-based microneedle systems, including material selection, fabrication strategies, and mechanisms of controlled drug release. Importantly, beyond conventional descriptive analysis, this work introduces a rational design framework that systematically integrates therapeutic objectives, polymer properties, mechanical performance, and release kinetics to guide the development of optimized microneedle platforms. The review further addresses key translational challenges, including mechanical limitations, manufacturing scalability, stability concerns, and regulatory considerations. In addition, emerging trends such as stimuli-responsive systems, nanocarrier integration, and personalized drug delivery approaches are discussed. Notably, data-driven strategies, including artificial intelligence (AI) and machine learning, are highlighted as promising tools for predicting system performance, optimizing formulation parameters, and accelerating the development of next-generation microneedle-based drug delivery systems. Overall, this work shifts the paradigm from empirical formulation toward a predictive, engineering-driven design strategy, offering valuable insights to advance the clinical translation of smart microneedle technologies.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1383-1404"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148991107","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Topical kojic acid liposomes for alkali-induced corneal injury: comparative study of uncoated vs. hyaluronic acid-coated formulations in corneal epithelial repair. 外用曲酸脂质体治疗碱性角膜损伤:未包被与透明质酸包被配方在角膜上皮修复中的比较研究。
IF 2.9 4区 医学
Pharmaceutical Development and Technology Pub Date : 2026-10-01 Epub Date: 2026-10-10 DOI: 10.1080/10837450.2026.2744579
Menna Mohy Eldeen, Mai Rady, Mohammad Abdel-Halim, Samar Mansour
{"title":"Topical kojic acid liposomes for alkali-induced corneal injury: comparative study of uncoated vs. hyaluronic acid-coated formulations in corneal epithelial repair.","authors":"Menna Mohy Eldeen, Mai Rady, Mohammad Abdel-Halim, Samar Mansour","doi":"10.1080/10837450.2026.2744579","DOIUrl":"10.1080/10837450.2026.2744579","url":null,"abstract":"<p><p>Corneal chemical injuries are ocular emergencies that can progress to severe ulceration, scarring, and vision loss. This study evaluated topically delivered kojic acid (KA), an agent known for cell proliferation and anti-inflammatory properties in an alkali-induced corneal injury model. Uncoated liposomes and HA coated liposomes were investigated to deliver KA in the corneal tissue. Small (∼200 nm; SL-KA, SL-KA-HA) and large (∼500 nm; LL-KA, LL-KA-HA) liposomes and HA coated liposomes were formulated. Larger liposomes either coated or uncoated exhibited superior <i>ex vivo</i> corneal retention compared to smaller nanocarriers, with uncoated large liposomes (LL-KA: 0.613 ± 0.02 µg) achieving higher retention than HA-coated liposomes (LL-KA-HA: 0.372 ± 0.04 µg). In a 21-day rabbit model of alkali-induced corneal injury, untreated controls showed persistent inflammation and cellular adhesion, whereas free KA failed to alleviate necrosis. Conversely, LL-KA and LL-KA-HA significantly enhanced structural healing, preserved intact epithelia, and reduced stromal alterations, with superior tissue recovery in the LL-KA group. HA solution controls preserved the epithelium but failed to resolve underlying stromal inflammation. Immunohistochemistry demonstrated a marked reduction in NF-κB expression in liposome-treated groups compared to untreated, free KA, or HA controls. Liposomal delivery of KA offers a promising non-surgical therapy for alkali-induced corneal injuries, with uncoated large liposomes emerged better corneal healing.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1500-1513"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149113566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction. 极性梯度萃取制备硫酸软骨素稳定艾塞那肽PLGA微球。
IF 2.9 4区 医学
Pharmaceutical Development and Technology Pub Date : 2026-10-01 Epub Date: 2026-09-18 DOI: 10.1080/10837450.2026.2731988
Ajay J Khopade, Arindam Halder, Vivek Patel, Mehul Joshi, Vinod Burade
{"title":"Development of chondroitin sulfate‑stabilized PLGA microspheres of exenatide via polarity gradient extraction.","authors":"Ajay J Khopade, Arindam Halder, Vivek Patel, Mehul Joshi, Vinod Burade","doi":"10.1080/10837450.2026.2731988","DOIUrl":"10.1080/10837450.2026.2731988","url":null,"abstract":"<p><p>The present work describes the development and optimization of a poly (lactide-<i>co</i>-glycolide) based sustained release injectable microsphere formulation of exenatide using a coacervation and in oil drying process. The internal phase composition, containing exenatide and stabilizer, was evaluated to identify critical parameters affecting stability, drug loading, particle morphology, and burst release of exenatide. Incorporation of chondroitin sulfate(0.5-2% w/w), formed stable uniform coacervates providing consistent particle size distribution, drug loading up to 4.7% w/w, initial burst (∼1.1%) and impurities, with 'shrunken' microsphere morphology. The secondary emulsification temperature of 2-8 °C produced smaller and more uniform particles. A gradient quenching process for hardening of microspheres using n-heptane: diethyl ether (1:9) to (10:0) provided low porosity and burst release relative to n-heptane alone. The drying and lyophilization conditions reduced residual solvent levels (<5000 ppm or below quantitation) and improved its wetting characteristics. The formulation remained stable for 24 months at 2-8 °C, with minimal loss of assay content. <i>In vitro</i> release showed controlled release for over one month. This translated into approximately 28 days of drug exposure in rat pharmacokinetic studies and sustained glycemic control for 28 days in a db/db mice, thus, correlating microsphere erosion, <i>in vitro</i> release, and <i>in vivo</i> outcomes. This study provides insight into the manufacturing process dynamics.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1325-1346"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148913031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Nanostructured mucoadhesive buccal tablets for apixaban delivery: mechanistic insights into transmucosal transport and systemic bioavailability. 用于阿哌沙班给药的纳米结构黏附口腔片:通过粘膜转运和全身生物利用度的机制见解。
IF 2.9 4区 医学
Pharmaceutical Development and Technology Pub Date : 2026-10-01 Epub Date: 2026-10-09 DOI: 10.1080/10837450.2026.2744568
Dalia A Gaber
{"title":"Nanostructured mucoadhesive buccal tablets for apixaban delivery: mechanistic insights into transmucosal transport and systemic bioavailability.","authors":"Dalia A Gaber","doi":"10.1080/10837450.2026.2744568","DOIUrl":"10.1080/10837450.2026.2744568","url":null,"abstract":"<p><p>This study developed and evaluated a nanoparticle-in-matrix mucoadhesive buccal delivery system for apixaban (APX) to improve its dissolution and systemic exposure. APX-loaded polymeric nanoparticles were prepared by antisolvent nanoprecipitation and incorporated into thiolated chitosan-Carbopol<sup>®</sup> buccal matrices by direct compression. The optimized nanoparticles exhibited a diameter of 195 ± 22 nm and a 6-fold increase in saturated solubility. The optimized tablets showed rapid hydration (55 ± 4 s), strong mucoadhesion, prolonged <i>ex vivo</i> mucosal retention (7.84 ± 0.41 h), and approximately 80% drug release within 10 min. <i>Ex vivo</i> studies demonstrated a mucosal penetration depth of 285 ± 18 μm. In rabbits, the optimized buccal formulation significantly increased Cmax (3950 ± 310 ng/mL) and AUC<sub>0</sub>-<sub>24</sub> (31,600 ± 2850 ng·h/mL) compared with marketed tablets (420 ± 55 ng/mL and 4120 ± 390 ng·h/mL, respectively), representing approximately 9.4-fold and 7.7-fold higher exposure (<i>p</i> < 0.05). Faster systemic absorption was also observed, with a Tmax of 0.75 ± 0.20 h and Ka of 1.48 ± 0.18 h<sup>-1</sup>. Changes in PT and aPTT were observed; however, these conventional assays have limited sensitivity for quantitatively assessing apixaban pharmacodynamic activity. Histopathological examination indicated favorable local tissue compatibility. Overall, the nanoparticle-in-matrix buccal system markedly enhanced and accelerated APX exposure in rabbits, supporting its potential for buccal delivery while emphasizing the need for dose optimization, pharmacodynamic assessment, and dedicated safety evaluation before clinical translation.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1478-1499"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149128228","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Chitosan-modulated niosomes for improved ocular delivery of brinzolamide. 壳聚糖调节乳小体改善溴唑胺眼部递送。
IF 2.9 4区 医学
Pharmaceutical Development and Technology Pub Date : 2026-10-01 Epub Date: 2026-10-13 DOI: 10.1080/10837450.2026.2744195
Marina K Sobhy, Abdelaziz E Abdelaziz, Eman A Mazyed, Ahmed A A Youssef, Aya R Elbasuony, Gamal M El Maghraby
{"title":"Chitosan-modulated niosomes for improved ocular delivery of brinzolamide.","authors":"Marina K Sobhy, Abdelaziz E Abdelaziz, Eman A Mazyed, Ahmed A A Youssef, Aya R Elbasuony, Gamal M El Maghraby","doi":"10.1080/10837450.2026.2744195","DOIUrl":"10.1080/10837450.2026.2744195","url":null,"abstract":"<p><p>Brinzolamide (BZ) is considered a promising pharmaceutical agent for lowering elevated intraocular pressure (IOP). However, its poor aqueous solubility limits its ocular bioavailability. Niosomes showed promising potential in ophthalmic delivery. Chitosan coating may extend the benefits of niosomes by imparting mucoadhesive potential. The aim of this investigation was to explore the potential of chitosan-coated niosomes (CS-niosomes) for improving the ocular delivery of BZ. Standard niosomes composed of Span 60, cholesterol, and ursodeoxycholic acid were loaded with BZ. The same system was coated with chitosan to provide CS-niosomes. Niosomes morphology, size, BZ entrapment efficiency and release were determined. The IOP-lowering effect of BZ-loaded niosomes was monitored after ocular administration in rabbits with experimentally induced glaucoma using lab-prepared suspension and marketed eye drops (Azopt<sup>®</sup>) as control. Standard niosomes and CS-niosomes were spherical vesicles having size of 193.50 and 159.90 nm, respectively. BZ was entrapped with efficiency of 90.02% and 88.43% in both systems, respectively, with no significant difference observed in their release behaviour. With respect to IOP-lowering ability, CS-niosomes > standard niosomes > Azopt<sup>®</sup> > lab-prepared suspension with CS-niosomes preserving the efficacy even after 10 h. This study demonstrated the potential of CS-niosomes as a promising nanocarrier for enhanced ocular delivery of BZ.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1465-1477"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149113564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Mucoadhesive tacrolimus formulations for buccal application: a formulation and drug delivery feasibility study for oral lichen planus. 口腔黏附他克莫司制剂:口腔扁平苔藓的制剂及给药可行性研究。
IF 2.9 4区 医学
Pharmaceutical Development and Technology Pub Date : 2026-10-01 Epub Date: 2026-10-06 DOI: 10.1080/10837450.2026.2738760
Alexander Hoffreiter, Emily Graf, Dominique Jasmin Lunter
{"title":"Mucoadhesive tacrolimus formulations for buccal application: a formulation and drug delivery feasibility study for oral lichen planus.","authors":"Alexander Hoffreiter, Emily Graf, Dominique Jasmin Lunter","doi":"10.1080/10837450.2026.2738760","DOIUrl":"10.1080/10837450.2026.2738760","url":null,"abstract":"<p><p>Tacrolimus is a potent calcineurin inhibitor suitable for the local treatment of oral mucosal immune-mediated diseases; however, no buccal formulation is currently available. The main objective of this work was to develop a mucoadhesive, semi-solid formulation containing tacrolimus that has adequate mucoadhesion salivation, and effective mucosal penetration with low systemic availability. A series of tacrolimus containing semisolid formulations based on chitosan, carbomer and hypromellose (HPMC) as mucoadhesive polymers were developed. Their rheologic behavior, pH value, macroscopic and microscopic properties as well as mucoadhesion and mucosal penetration were investigated. Lactate buffer was successfully used to stabilize chitosan against hydrolysis. It was shown that diols of different chain length, like 1,2-propanediol 1,2-pentanediol and 1,2-hexanediol improved mucosal penetration but reduced mucoadhesion due to gel matrix weakening. After 60 min in the mucoadhesion cell, mucosal tacrolimus amounts versus salivary wash-off for the diols were 0.78 ± 0.09 µg/cm<sup>2</sup> versus 0.47 ± 0.20% for 20% 1,2-propanediol, 1.99 ± 0.23 µg/cm<sup>2</sup> versus 14.26 ± 3.01% for 40% 1,2-propanediol, 3.56 ± 0.29 µg/cm<sup>2</sup> versus 25.04 ± 1.68% for 20% 1,2-pentanediol, and 3.66 ± 0.25 µg/cm<sup>2</sup> versus 28.13 ± 4.00% for 20% 1,2-hexanediol. A series of tacrolimus formulations with different degrees of mucoadhesion, salivary retention and penetration characteristics was successfully developed.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1425-1448"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149039967","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Preparation and in vitro evaluation of amphotericin B-chondroitin sulfate polymer prodrug. 两性霉素b -硫酸软骨素聚合物前药的制备及体外评价。
IF 2.9 4区 医学
Pharmaceutical Development and Technology Pub Date : 2026-10-01 Epub Date: 2026-09-29 DOI: 10.1080/10837450.2026.2740069
Jingqiu Sun, Qingyun Yu, Weijun Chen, Lingtong Ge, Anran Jiao, Haoxin Ding, Lipeng Qiu, Qingfeng Guo
{"title":"Preparation and <i>in vitro</i> evaluation of amphotericin B-chondroitin sulfate polymer prodrug.","authors":"Jingqiu Sun, Qingyun Yu, Weijun Chen, Lingtong Ge, Anran Jiao, Haoxin Ding, Lipeng Qiu, Qingfeng Guo","doi":"10.1080/10837450.2026.2740069","DOIUrl":"10.1080/10837450.2026.2740069","url":null,"abstract":"<p><p>Amphotericin B (AmB) remains the gold-standard antifungal agent, yet its clinical utility is severely limited by dose-dependent hemolytic and nephrotoxic side effects arising from its aggregation-prone nature and non-selective membrane binding. To address this challenge, we developed a polymer prodrug by conjugating AmB to oxidized chondroitin sulfate (CSox) <i>via</i> a Schiff-base linkage designed to be pH-labile, selected for CS's CD44-targeting capability, intrinsic anti-inflammatory activity, and favorable polyelectrolyte properties. The resulting CSox-AmB conjugate self-assembled into uniform micelles (141.60 ± 4.03 nm, zeta potential -25.47 ± 0.59 mV) with a drug loading of 7.07 ± 0.13%, maintaining AmB predominantly in its monomeric state (A<sub>348</sub>/A<sub>409</sub> = 0.865 < 1). The prodrug exhibited sustained release (∼68% at 24 h) while preserving antifungal activity comparable to free AmB against Candida albicans. Concurrently, it attenuated mammalian cell cytotoxicity by 2.3- to 2.5-fold and markedly attenuated hemolytic activity <i>in vitro</i> (<1% at 25 μg·mL<sup>-1</sup>). This integrated design-conjugation enabling self-assembly, assembly enabling monomeric stabilization, and controlled release enabling efficacy with markedly reduced toxicity-positions CSox-AmB as a promising prodrug strategy that uncouples the antifungal activity of AmB from its inherent toxicities, warranting further <i>in vivo</i> evaluation toward clinical translation.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1449-1464"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149063343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Engineered nanostructured lipid carrier encapsulating thymoquinone and resveratrol to prevent Bisphenol S induced cytotoxicity. 包封百里醌和白藜芦醇的纳米结构脂质载体防止双酚S诱导的细胞毒性。
IF 2.9 4区 医学
Pharmaceutical Development and Technology Pub Date : 2026-10-01 Epub Date: 2026-09-21 DOI: 10.1080/10837450.2026.2734054
Garima Sagar, Alok Kumar, Neha Singh, Vikas Srivastava, Somendu Kumar Roy
{"title":"Engineered nanostructured lipid carrier encapsulating thymoquinone and resveratrol to prevent Bisphenol S induced cytotoxicity.","authors":"Garima Sagar, Alok Kumar, Neha Singh, Vikas Srivastava, Somendu Kumar Roy","doi":"10.1080/10837450.2026.2734054","DOIUrl":"10.1080/10837450.2026.2734054","url":null,"abstract":"<p><p>Nanostructured lipid carriers (NLCs) are diverse colloidal systems that enhance the solubility, stability, and bioavailability of bioactive compounds. Herein, we developed a co-loaded NLC encapsulating thymoquinone (TQ) and resveratrol (RV) to enhance prevention against globally emerging endocrine disruptor bisphenol S (BPS) induced cytotoxicity in NRK-52E cells. The formulation components were rationally optimised, achieving high encapsulation efficiencies for TQ (99.42% ± 0.08) and RV (98.60% ± 0.12), a particle size of 123.66 ± 6.32 nm, and a polydispersity index of 0.37 ± 0.04, indicating stable, homogeneous, quasi-spherical particles as observed in TEM. Interfacial encapsulation and reduced crystallinity observed by FTIR and XRD analyses, respectively, supported the formation of an imperfect core-shell structure. The drug-release profile indicated a diffusion-dominated, matrix-relaxation-assisted transport mechanism. <i>In vitro</i> assays demonstrated a strong cytoprotective effect of TQRV-NLCs at 0.01 μg/mL, comparable to 1 μg/mL free drugs, indicating a significant improvement in therapeutic efficacy. TQRV-NLCs markedly reduced BPS-induced oxidative stress, mitochondrial depolarisation, loss of cell migration, and loss of membrane integrity, while restoring membrane integrity, normalising cell cycle distribution, and preserving nuclear morphology in NRK-52E cells. In summary, this study provides proof of concept that TQRV-NLCs markedly enhance efficacy, confer superior cytoprotection, and offer preventive effects, presenting a promising strategy for renal protection against BPS.</p>","PeriodicalId":20004,"journal":{"name":"Pharmaceutical Development and Technology","volume":" ","pages":"1347-1367"},"PeriodicalIF":2.9,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148963602","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书